|
05 Jun 2020 |
European Commission Grants Marketing Authorisation for DARZALEX (daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications
|
|
05 Jun 2020 |
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
|
|
03 Jun 2020 |
Sanofi European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma
|
|
03 Jun 2020 |
Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress
|
|
03 Jun 2020 |
Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza™ (naxitamab) for the Treatment of Neuroblastoma for Priority Review
|
|
03 Jun 2020 |
Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
|
|
03 Jun 2020 |
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
|
|
02 Jun 2020 |
FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
|
|
02 Jun 2020 |
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
|
|
02 Jun 2020 |
Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Graves’ Ophthalmopathy
|
|
01 Jun 2020 |
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
|
|
01 Jun 2020 |
Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
|
|
01 Jun 2020 |
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
|
|
01 Jun 2020 |
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
|
|
01 Jun 2020 |
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|
|
01 Jun 2020 |
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time
|
|
31 May 2020 |
Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
|
|
31 May 2020 |
CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
|
|
30 May 2020 |
Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases
|
|
30 May 2020 |
Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020
|
|
30 May 2020 |
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
|
|
30 May 2020 |
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
|
|
30 May 2020 |
SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate
|
|
29 May 2020 |
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
|
|
29 May 2020 |
Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia
|
